How to verify Melanotan II purity and batch documentation

Melanotan II (MT-II), also referred to as melanotan 2, is a synthetic cyclic peptide analogue belonging to the melanocortin hormone family. It is an unlicensed compound and is not approved for human use in any jurisdiction [1]. The evidence block provided for this page does not supply a sequence, molecular formula or molecular weight for Melanotan II, so no such identifiers are stated here. The work described in the evidence centres on the melanocortin receptor family, a group of Class A G protein-coupled receptors (GPCRs) that includes five subtypes, MC1R through MC5R, with MC1R expressed on melanocytes and MC2R being the receptor for ACTH [1][6].

Verification of a research peptide such as Melanotan II rests on three separable questions: whether the material is the intended molecule, whether it is pure, and whether the batch documentation is internally consistent. The evidence summarised below addresses analytical identification of the compound in submitted samples, receptor-level pharmacology, and reported observations in specific models. Where a finding comes from animal or in vitro work, or from a single case, this is stated plainly.

Research Studies

Melanotan II and analytical identification in submitted samples

A laboratory identification study examined samples submitted for analysis, including two vials with a pharmaceutical appearance. The powder contained in the vial was characterised using HPLC-DAD, UHPLC-TOF-MS, and/or UPLC-MS-MS [5]. This is the analytical context in which identity testing of a research peptide sits: chromatographic separation coupled to mass spectrometric detection, used to establish what a powder actually contains rather than what its label states. The study is a reference point for method choice, not a purity specification.

Melanotan II and melanocortin receptor pharmacology

Melanotan II acts primarily by activating melanocortin 1 receptors on melanocytes, stimulating eumelanin production and producing skin pigmentation independent of sun exposure [1]. The melanocortin receptors are a centrally and peripherally expressed family of Class A GPCRs with physiological roles that include pigmentation, steroidogenesis and energy homeostasis, and there are five receptor subtypes, with MC2R being distinct from the others [6]. Receptor-level characterisation of tool compounds for this family is therefore the framework within which MT-II activity is described, and it is in vitro and pharmacological work rather than a clinical endpoint.

Melanotan II and oral mucosal pigmentation in a reported case

A case report followed a patient who self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect, with a three-month follow-up. During the initial intraoral examination, brown pigmentation was observed [1]. This is a single-patient observation and cannot establish incidence or causation; it is reported here as what the case documented.

Melanotan II and oral mucosal findings in a second reported case

A separate report described a 22-year-old female who developed a mass in the anterior maxilla after using a Melanotan II nasal spray for tanning purposes. The spray contained a synthetic analogue of melanocyte-stimulating hormone. The report notes that Melanotan II is unlicensed and that its sale is illegal in the United Kingdom [3]. As with the preceding case, this is a single-patient report and does not support generalisable risk estimates.

Melanotan II and repigmentation in stable nonsegmental vitiligo

A randomised Phase 2 clinical trial record describes investigational Melanotan II as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo [2]. This is a registered interventional study in a defined adult population; the record describes the design and does not, in the evidence supplied, report outcomes.

Melanotan II and stress-related behaviour in male rats

In male rats exposed to a chronic unpredictable stress model, the ACTH(4-10) synthetic analogues Semax and Melanotan II were studied for antidepressant-like and antistress effects. The rationale given is that stressful events and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis are important in the pathogenesis of depression [4]. This is animal-only evidence in a specific model and does not translate to human behavioural or clinical outcomes.

Melanotan II and batch documentation: what the evidence supports

None of the sources in the evidence block provides a certificate-of-analysis template, a purity threshold, or a batch-release specification for Melanotan II. What the evidence does support is the analytical toolkit: HPLC-DAD, UHPLC-TOF-MS and UPLC-MS-MS were the methods used to identify the contents of submitted vials [5], and receptor-family characterisation of melanocortin tool compounds is described in the pharmacological literature [6]. Any documentation review should therefore be checked against the methods actually named in the source material rather than against assumed values.

Melanotan II and the limits of the available evidence

The evidence block contains no study reporting a measured purity percentage, no validated limit for related substances, and no comparison of batch documentation against an accepted standard. Claims about a specific purity figure or a specific documentation format would therefore be unsupported by these sources and are not made here. What can be stated is that identity testing of a peptide powder has been performed by chromatographic and mass spectrometric methods [5], and that the receptor pharmacology of the melanocortin family is documented in vitro [6].

Melanotan II and regulatory status as a documentation question

Melanotan II is described in the evidence as unlicensed, with sale reported as illegal in the United Kingdom, and as unregulated despite its popularity and promotion on social media [1][3]. For a research-supply context, regulatory status is a documentation matter: it determines what a supplier may lawfully describe, not what a laboratory may analyse. The sources do not provide a jurisdiction-by-jurisdiction table, and none is constructed here.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page is medical advice. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report — https://europepmc.org/article/PMC/PMC12942211
• [2] Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo — https://clinicaltrials.gov/study/NCT07437560
• [3] Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? — https://pubmed.ncbi.nlm.nih.gov/40210573/
• [4] Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress — https://pubmed.ncbi.nlm.nih.gov/39442746/
• [5] Barbie drug identification: Not a child's play — https://pubmed.ncbi.nlm.nih.gov/39302005/
• [6] Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs) — https://europepmc.org/article/PMC/PMC11406693